Maxx Orthopedics commenced commercial launch and announced first successful surgeries using its new Libertas® Taper Reduced (TR) Uncemented Femoral Stem.
Libertas TR is a press fit, double tapered stem with Ti-GrowthC® coating offered in standard and distally reduced versions. The stems are available in three neck angles to accommodate patient-specific anatomic requirements and are compatible with Maxx’s existing Libertas Femoral Heads, as well as the Libertas Acetabular Cup. The proximal Ti-GrowthC coating on the implant surface is designed to promote biological integration with bone for longer-term stability, while the geometry of the stem aids in providing a better fit for proximal and distal mismatches.
“[The] Libertas TR is in limited release now, and we expect full commercial release within three months. As a company this launch is particularly invigorating as we continue to battle the challenges posed by COVID-19,” said Ashesh Shah, Chief Executive Officer.
Maxx Orthopedics commenced commercial launch and announced first successful surgeries using its new Libertas® Taper Reduced (TR) Uncemented Femoral Stem.
Libertas TR is a press fit, double tapered stem with Ti-GrowthC® coating offered in standard and distally reduced versions. The stems are available in three neck angles to accommodate...
Maxx Orthopedics commenced commercial launch and announced first successful surgeries using its new Libertas® Taper Reduced (TR) Uncemented Femoral Stem.
Libertas TR is a press fit, double tapered stem with Ti-GrowthC® coating offered in standard and distally reduced versions. The stems are available in three neck angles to accommodate patient-specific anatomic requirements and are compatible with Maxx’s existing Libertas Femoral Heads, as well as the Libertas Acetabular Cup. The proximal Ti-GrowthC coating on the implant surface is designed to promote biological integration with bone for longer-term stability, while the geometry of the stem aids in providing a better fit for proximal and distal mismatches.
“[The] Libertas TR is in limited release now, and we expect full commercial release within three months. As a company this launch is particularly invigorating as we continue to battle the challenges posed by COVID-19,” said Ashesh Shah, Chief Executive Officer.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
